Natalizumab (Tysabri)
From: Rigshospitalet, Neurocentret, Dansk Multipel Sklerose Center, København Ø. mads.ravnborg@rh.hosp.dk
Ugeskrift for laeger
- Publish Date: Sep 2007
- ISSN: 1603-6824
- Volume: 169
- Issue: 38
- Pages: 3184-7
- Medium: Internet
- Language:
- Citation (JAMA): Ravnborg Mads, et al. Natalizumab (Tysabri). Ugeskr. Laeg. Sep 2007;169:3184-7
Abstract
Natalizumab is a humanized recombinant monoclonal antibody against alpha4-intigrin. In a large phase III study on relapsing-remitting MS Natalizumab reduced the relapse rate by 68% and the appearance of permanent neurological deficits by 42%. Currently, Natalizumab is the most effective disease-modifying treatment of relapsing-remitting MS. The clinical use of the treatment will be restricted initially due to uncertainty about the risk of opportunistic infections in long term treatment.
Mesh Headings (Keywords): Antibodies, Monoclonal, Humans, Multiple Sclerosis, Risk Factors, Treatment Outcome
Check for Full Text / PubMed Unique Identifier (PMID): 17910826
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.